1-4 of 4
Andrew Zelenetz, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell Lymphoma: A Single Institution Experience.

Martin Voss, MD, Andrew Zelenetz, MD, PhD, Esperanza B. Papadopoulos, MD, Hanna Weissbrot, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2007) 110 (11): 3454.
https://doi.org/10.1182/blood.V110.11.3454.3454
Published: 2007
Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 2759.
https://doi.org/10.1182/blood.V108.11.2759.2759
Published: 2006
Journal Articles

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Steven Horwitz, MD, Craig Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, David Straus, MD, Owen O’Connor, MD, PhD, Ariela Noy, MD, Carol Portlock, MD, Stephen Nimer, MD, PhD, M. Lia Palomba, MD, PhD, Andrew Zelenetz, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2679.
https://doi.org/10.1182/blood.V106.11.2679.2679
Published: 2005
Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD
Journal: Blood
Blood (2004) 104 (11): 607.
https://doi.org/10.1182/blood.V104.11.607.607
Published: 2004